

- 1 . . . , . . . "
- 1 . . . , . . . "
- 2 . . . , . . . "
- 2 . . . , . . . " . . . "
- 2 . . . , . . . " . . . "

- 1 ,
- 2 « »,

157 443 1

212 1
15 [10].

[24, 25].

[9, 15].

()

"

("Himalaya"),
("KRKA"),
("IVAX-CR").

("UCB Healthcare"),

("Bionorica AG"),

[9, 26].

«

».
(*Orthosiphon stamineus* Benth.),
(*Polygonum aviculare* L.),
(*Arctostaphylos uva-ursi* L.),
(*Desmodium canadensis* (L.) D.S.),
4,0:3,5:2,0:0,5

[17, 18].

[15, 20, 22].

7-

(15,12%),

(12,90%)

(10,00%)

; 16,40%

[18].
 L.),
 L.),
 (Polygonum aviculare
 (Arctostaphylos uva-ursi
 (Vaccinium vitis idaea L.),
 (Urtica dioica L.)
 (Calendula officinalis L.),
 3,0:2,0:2,0:1,5:1,5
 (Comarum palustre.L.).

[16, 17].
 « »
 -7-O-P-D-

[17].

capitata () - Lespedeza
 Lespedeza bicolor Turcz. [7, 12].
 (,

) [11, 12].
 « »
 (),
 [4, 5].

[5, 13].
 [5, 6].

(
 (3-
), 7-

[3, 24].

[24, 25].

[21].

[8, 28].

(Lab. Darcy) .

[23].

[29].

[14, 19].

[29,30].

[2, 3, 27].

».

1. 2002.- 6, 4.- 92-93. // 13. 1978.- 1.- 136-137 (([24, 25].

2. // 14. (1920-2000).- : 2000.- 515 80-

3. 990.- 2 2-2 . // 15. [.]- : 2007.- 763 .

78-86. // 16. [.]- , 1997. . 9. . 66.

4. // 17. -2006.- 22

3. 99.- 208-209. // 18. 2006.- 5, / 2.- 109-110. //

6. 999.- 3-4.- 27-38. // 19. // « 2. » / 2003.- 44,

(992- 997). . 4. // 20. 2010. - 1216 .

7. // 998.- 6.- 6-24. // 21. // 2009. - 50 .

8. 970.- 4.- 473 // 22. // - 1998.- 6.- 58-62.

9. 98.- 90- 9 . // 23. : , 1995. - .1 — 496 . - 2 — 416 .

10. // 989.- 433 . // 24. // .419-420. // - 2008.- 510 .

- 2, - 42-48. // -200. // 25. // -1996.- 1.- 78-82.

11. (Lespedeza). //

12. 979.- 2.- 28- . // *Lespedeza hedysaroides*

17-22. []// . - 2002. - 2. - .
 26. / . . - . : ,
 - 2000. - 668 .
 27. « »
 »
 2001.- 3 (27).- . 161.
 28. Morris K.P., *Non cardiac benefits of human erythropoietin in*
615.322:615.254.7

endstage renal failure and anemia / K.P. Morris, J. Sharp, S. Watson [et al.]//Arch. Dis. Child. 1993.- N 69.- P. 580-586.
 29. Uribarri J. *A reevaluation of the minary parameters of acid production and excretion in patients with chronic renal acidosis /J. Uribarri, H. Douyon, M.S. Oh //Kidney Int. 1995.-N47.-P.624-627.*
 30. Vasta E.*Induction of specific transport system for L-arginine in human platelets /E. Vasta, M. Meacci [et al.]//Biochem. Biophys. Res. Commun. 1995.- Vol. 206, N3.-P. 878-884.*

29.06.2011

N.V. Popova, S.I. Dikhtyarev, N.F. Maslova,
 V.I. Litvinenko, L.G. Almakaeva
HEALING OF KIDNEY DISEASES WITH HERBAL DRUGS

Key words: kidney, medications, natural compounds, flavonoids
 In the article the results of the generalization of market of medicinal preparations are presented for a prophylaxis and treatment on the basis of natural compounds which can be utilized as potential substances for application as medications and in particular flavonoids for a prophylaxis and treatment of kidney diseases.

615.371: 578.74

• . . ,
 • . . ,
 • . . ,

Therapeutics Groupe Limagrain Meristem

[1].

[1, 2, 6].

[8, 10].